Research Article
Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana
Table 3
MetS among studied subjects treated with atypical and typical antipsychotics.
| | Variables | Total | Atypical | Typical | | | | | n=159 | n=105 | n=54 | OR (95% CI) | p-value |
| | Met / NCEP/ATP III | | | | | | | 0 | 12(7.5) | 6(5.7) | 6(11.1) | 1 | | | 1 | 65(41.3) | 41(39.1) | 24(44.5) | 1.7(0.5-5.9) | 0.522 | | 2 | 58(36.2) | 40(38.1) | 18(33.3) | 2.2(0.6-7.8) | 0.316 | | ≥3 | 24(15.0) | 18(17.1) | 6(11.1) | 3.0(0.6-12.9) | 0.157 | | Met / IDF | | | | | | | 0 | 8(5.0) | 4(3.8) | 4(7.4) | 1 | | | 1 | 50(31.5) | 26(24.8) | 24(44.5) | 1.1(0.1-9.0) | 1.000 | | 2 | 56(35.2) | 44(41.9) | 12(22.2) | 3.7(0.8-16.9) | 0.099 | | ≥3 | 45(28.3) | 31(29.5) | 14(25.9) | 2.2(0.5-10.2) | 0.421 | | Met / WHO | | | | | | | 0 | 12(7.6) | 6(5.7) | 6(11.1) | 1 | | | 1 | 53(33.3) | 34(32.0) | 19(35.2) | 1.8(0.5-6.3) | 0.512 | | 2 | 55(34.6) | 36(34.0) | 19(35.2) | 1.9(0.5-6.7) | 0.341 | | ≥3 | 39(24.5) | 29(44.3) | 10(18.5) | 2.9(0.8-11.1) | 0.157 |
|
|
NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization; MetS: metabolic syndrome; OR: odds ratio; CI: confidence interval; p<0.05 is statistically significant.
|
